AR and prostate cancer: Increase in the level of AR-V7 with a truncated C-terminus, which could not be inhibited by the ligand-binding domain inhibitor, enzalutamide, caused continuous activation of AR signals, resulting in prostate cancer resistance to enzalutamide.